💨 Abstract

Voyager Therapeutics reported a $33.4 million loss in Q2 2025, with a per-share loss of 57 cents, missing Wall Street’s expectations of a 48 cents per-share loss. Revenue was $5.2 million, significantly below the forecasted $11.7 million. The gene therapy company fell short on both earnings and revenue fronts.

Courtesy: WTOP Staff